Cargando…

New combinations in the treatment of COPD: rationale for aclidinium–formoterol

The current guidelines on chronic obstructive pulmonary disease (COPD) recommend the prominent use of bronchodilators, including long-acting β(2)-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs), while inhaled corticosteroids are recommended only in patients with severe disease or fre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Incorvaia, Cristoforo, Montagni, Marcello, Makri, Elena, Ridolo, Erminia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760652/ https://www.ncbi.nlm.nih.gov/pubmed/26929634 http://dx.doi.org/10.2147/TCRM.S82034

Ejemplares similares

Striving for optimal bronchodilation: focus on olodaterol
por: Incorvaia, Cristoforo, et al.
Publicado: (2016)

Bilastine: new insight into antihistamine treatment
por: Ridolo, Erminia, et al.
Publicado: (2015)

Role of indacaterol and the newer very long-acting β2-agonists in patients with stable COPD: a review
por: Ridolo, Erminia, et al.
Publicado: (2013)

Aclidinium bromide/formoterol fixed-dose combination therapy for COPD: the evidence to date
por: Moitra, Subhabrata, et al.
Publicado: (2015)

Characteristics of New Users of Aclidinium Bromide, Aclidinium/Formoterol, and Other COPD Medications in the United Kingdom, Denmark, and Germany
por: Rivero-Ferrer, Elena, et al.
Publicado: (2022)

Efficacy and Safety of Aclidinium/Formoterol versus Tiotropium in COPD: Results of an Indirect Treatment Comparison
por: Medic, Goran, et al.
Publicado: (2016)

Aclidinium bromide in fixed-dose combination with formoterol fumarate in the management of COPD: an update on the evidence base
por: D’Urzo, Anthony D., et al.
Publicado: (2019)

Two decades with omalizumab: what we still have to learn
por: Incorvaia, Cristoforo, et al.
Publicado: (2018)

Current treatment strategies for seasonal allergic rhinitis: where are we heading?
por: Ridolo, Erminia, et al.
Publicado: (2022)

Specific role of combination aclidinium: formoterol in the treatment of chronic obstructive pulmonary disease
por: Matera, Maria Gabriella, et al.
Publicado: (2016)

Patient-reported outcomes and considerations in the management of COPD: focus on indacaterol/glycopyrronium bromide
por: Ridolo, Erminia, et al.
Publicado: (2019)

ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD
por: Watz, Henrik, et al.
Publicado: (2017)

What still prevents to acknowledge a major role for pulmonary rehabilitation in COPD treatment?
por: Incorvaia, Cristoforo, et al.
Publicado: (2019)

New product development with the innovative biomolecular sublingual immunotherapy formulations for the management of allergic rhinitis
por: Frati, Franco, et al.
Publicado: (2014)

Lipid transfer protein syndrome: How to save a life through careful education
por: Ridolo, Erminia, et al.
Publicado: (2022)

Preventive actions of allergen immunotherapy: the facts and the effects in search of evidence
por: Martignago, Irene, et al.
Publicado: (2017)

Can the Pattern of Early Sensitization to Allergen Molecules Drive a New Approach for Prevention of Allergy?
por: Incorvaia, Cristoforo, et al.
Publicado: (2017)

Differential Outcomes Following 4 Weeks of Aclidinium/Formoterol in Patients with COPD: A Reanalysis of the ACTIVATE Study
por: Koopman, Maud, et al.
Publicado: (2022)

The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis
por: Miravitlles, Marc, et al.
Publicado: (2016)

Clinical use of aclidinium in patients with COPD
por: Reid, Debra J, et al.
Publicado: (2014)

Pharmacoeconomics of sublingual immunotherapy with the 5-grass pollen tablets for seasonal allergic rhinitis
por: Lombardi, Carlo, et al.
Publicado: (2017)

Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study
por: D’Urzo, Anthony D, et al.
Publicado: (2014)

Allergen immunotherapy for house dust mite-induced rhinitis: prescriptive criteria
por: Incorvaia, Cristoforo, et al.
Publicado: (2021)

Use of concomitant inhaled corticosteroids: pooled data from two phase III studies of aclidinium plus formoterol in COPD
por: D’Urzo, Anthony, et al.
Publicado: (2017)

Cost versus utility of aclidinium bromide 400 µg plus formoterol fumarate dihydrate 12 µg compared to aclidinium bromide 400 µg alone in the management of moderate-to-severe COPD
por: Ramos, Mafalda, et al.
Publicado: (2016)

Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol
por: Singh, Dave, et al.
Publicado: (2017)

Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study
por: Singh, Dave, et al.
Publicado: (2014)

Will Research on COVID-19 Stimulate the Identification of Immunological Mechanisms Underlying Some Protective Effects?
por: Incorvaia, Cristoforo, et al.
Publicado: (2021)

Personalized medicine and allergen immunotherapy: the beginning of a new era?
por: Incorvaia, Cristoforo, et al.
Publicado: (2021)

Which immunotherapy product is better for patients allergic to Polistes venom? A laboratory and clinical study
por: Savi, Eleonora, et al.
Publicado: (2017)

About the effect of pulmonary rehabilitation on lung function in patients with chronic obstructive pulmonary disease
por: Incorvaia, Cristoforo, et al.
Publicado: (2016)

Assessing the Risk Factors for Refractory Eosinophilic Esophagitis in Children and Adults
por: Ridolo, Erminia, et al.
Publicado: (2019)

IgE Depletion in Severe Asthma: What We Have and What Could Be Added in the Near Future
por: Incorvaia, Cristoforo, et al.
Publicado: (2017)

The quest for improving general and in hospital health care during COVID-19 pandemic
por: Ridolo, Erminia, et al.
Publicado: (2021)

Allergists and COVID-vaccine: which is the actual risk of reactions in allergic patients?
por: Pucciarini, Francesco, et al.
Publicado: (2022)

Effectiveness and Tolerability of LABA/LAMA Fixed-Dose Combinations Aclidinium/Formoterol, Glycopyrronium/Indacaterol and Umeclidinium/Vilanterol in the Treatment of COPD in Daily Practice – Results of the Non-Interventional DETECT Study
por: Plate, Tanja, et al.
Publicado: (2020)

Is aclidinium alone or combined with a LABA a rational choice for symptomatic COPD patients?
por: Blasi, F., et al.
Publicado: (2017)

Effects of aclidinium on determinants of COPD severity: symptoms and quality of life
por: Contoli, Marco, et al.
Publicado: (2016)

The Present and Future of Allergen Immunotherapy in Personalized Medicine
por: Ridolo, Erminia, et al.
Publicado: (2022)

Budesonide/formoterol combination in COPD: a US perspective
por: Sharafkhaneh, Amir, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_lb4gvmcah3787eec2785pecpq2